BTF3在肝癌恶性进展中的作用及其临床应用价值

陈 璐1, 张 道畅1, 方 志俊1, 沈 建江2, 周 越3, 张丽 红*3
1、绍兴文理学院医学院
2、嵊州市人民医院（浙江大学医学院附属第一医院嵊州分院）检验科
3、绍兴市人民医院医学检验科

摘要


目的：评估BTF3对肝癌诊断及预后判断的临床价值，探讨BTF3促进肝癌恶性进展的作用及机制。方法：（1）利用生物信息学数据库和免疫组化分析BTF3在肝癌组织中的表达及其与患者预后的关系。（2）构建BTF3干扰细胞株，应用平板克隆、Transwell实验检测肝癌细胞增殖、迁移和侵袭的能力。（3）生信分析、Western blot等方法筛选并验证BTF3共表达蛋白及下游信号通路。结果：（1）BTF3在肝癌组织中呈现高表达，且其表达水平与肿瘤临床分期相关。BTF3高表达预示患者预后不良。（2）干扰BTF3后，肝癌细胞的增殖、迁移和侵袭能力下降。（3）BTF3、NACA与YAP1的表达存在正相关。干扰BTF3后，NACA与YAP1表达水平均下降。敲减BTF3同时过表达YAP1后，肝癌细胞的迁移和侵袭能力得到部分回复。结论：BTF3在肝癌组织中高表达，其表达水平与患者预后显著相关，可能可以作为肝癌诊断和预后的潜在标志物。BTF3可能与NACA互作通过调控Hippo信号通路促进肝癌恶性进展。

关键词


BTF3；肝癌；Hippo信号通路

全文:

PDF


参考


[1]Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology, 2023, 77(5):1773-1796.

[2]Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3):229-263.

[3]Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin, 2025, 75(1):10-45.

[4]Zheng J, Wang S, Xia L, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther, 2025, 10(1):35.

[5]Guan MC, Wang MD, Liu SY, et al. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol, 2021, 13(4):197-215.

[6]Zhang Y, Gao X, Yi J, et al. BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. Cell Death Dis. 2021, 12(1):12.

[7]Wang H, Xing J, Wang W, et al. Molecular Characterization of the Oncogene BTF3 and Its Targets in Colorectal Cancer. Front Cell Dev Biol, 2021, 8:601502.

[8]Li C, Wang K, Zhao L, et al. LINC00622 transcriptionally promotes RRAGD to repress mTORC1-modulated autophagic cell death by associating with BTF3 in cutaneous melanoma. Cell Death Dis, 2025, 16(1):515.

[9]Cui Y, Pu M, Gong Y, et al. METTL3-driven m6A modification of lncRNA FAM230B suppresses ferroptosis by modulating miR-27a-5p/BTF3 axis in gastric cancer. Biochim Biophys Acta Gen Subj, 2024, 1868(11):130714.

[10]杜丹，黄贵闽，曹贵华，等.膀胱癌组织miR-361-5p、BTF3表达变化及临床意义.国际泌尿系统杂志，2023，43（1）：58-62.

[11]Zhang Y, Gross N, Li Z, et al. Upregulation of BTF3 affects the proliferation, apoptosis, and cell cycle regulation in hypopharyngeal squamous cell carcinoma. Biomed Pharmacother, 2019, 118:109211.

[12]Liu Q, Wu J, Lu T, et al. Positive expression of basic transcription factor 3 predicts poor survival of colorectal cancer patients: possible mechanisms involved. Cell Death Dis, 2019, 10(7):509.

[13]Zhou W, Yun Z, Wang T, et al. BTF3-mediated regulation of BMI1 promotes colorectal cancer through influencing epithelial-mesenchymal transition and stem cell-like traits. Int J Biol Macromol, 2021, 187:800-810.

[14]Jeon YJ, Bang W, Cho JH, et al. Kahweol induces apoptosis by suppressing BTF3 expression through the ERK signaling pathway in non-small cell lung cancer cells. Int J Oncol, 2016, 49(6):2294-2302.

[15]刘霄霄，王菲，杨冬梅等.基于生物信息学分析皮肤鳞癌的关键基因和免疫组化验证.中华老年医学杂志，2025，44（5）：621-627.

[16]Athavale D, Balch C, Zhang Y, et al. The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives. Cancer Lett, 2024, 604:217244.

[17]Li S, Hao L, Li N, et al. Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review). Int J Oncol, 2024, 65(3):88.


Refbacks

  • 当前没有refback。